JAQBO
LIVE

Serial Number

79383436

Owner

JEIL PHARMACEUTICAL CO., LTD

Attorney

John M. Kim

Filing Date

Sep 14, 2023

Add to watchlist:

No watchlists yet
View on USPTO

JAQBO Trademark

Serial Number: 79383436 • Registration: 7592609

JAQBO is a trademark filed by JEIL PHARMACEUTICAL CO., LTD on September 14, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

JEIL PHARMACEUTICAL CO., LTD

343, Sapyeong-daero, Seocho-gu

Entity Type: 03

Trademark Details

Filing Date

September 14, 2023

Registration Date

December 10, 2024

Published for Opposition

October 8, 2024

Goods & Services

Veterinary pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; proton-pump inhibitor, namely, medicines for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; medicines for the prevention and treatment of gastrointestinal diseases; medicines for the treatment of gastrointestinal diseases; medicines for human purposes, namely, medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; ethical medicinal preparations, namely, medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 6, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 15, 2025 FICS
FINAL DISPOSITION PROCESSED
May 15, 2025 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 3, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 15, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 15, 2025 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 10, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 10, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 10, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 8, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 8, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 18, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 3, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 3, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 3, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 3, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 3, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 30, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 30, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 30, 2024 TROA
REFUSAL PROCESSED BY IB
Jun 11, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 10, 2024 RFCS
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 10, 2024 RFCR
NON-FINAL ACTION WRITTEN
May 9, 2024 CNRT
ASSIGNED TO EXAMINER
May 9, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 24, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 20, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 16, 2023 REPR